EGFR and non-small cell lung carcinoma: Approximately half of the NSCLC tumors found in patients who initially responded to first-generation EGFR TKIs and then develop resistance have another mutation, known as the T790M point mutation in EGFR (Sharma et al., 2007; Suda et al., 2009).